Filtered By:
Management: Food and Drug Administration (FDA)
Procedure: Transplants
This page shows you your search results in order of date.
Order by Relevance | Date
Total 293 results found since Jan 2013.
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research
Multiple Administration Routes, Including Intramuscular Injection, of Oncolytic Tanapoxvirus Variants Significantly Regress Human Melanoma Xenografts in BALB/c Nude Mice Reconstituted with Splenocytes from Normal BALB/c Donors
In this study, TPV/Δ66R/mIL-2 and TPV/Δ2L/Δ66R/FliC were tested for their ability to treat human melanoma xenografts (SK-MEL3) in a BALB/c nude mouse model reconstituted with splenocytes from genetically compatible, normal BALB/c donor mice. Two SK-MEL3 tumors were transplanted into each flank of BALB/c nude mice, and the larger tumor was treated intratumorally (IT) with virus or mock injection. In one set of animals, mice received adoptive transfers of splenocytes from BALB/c mice on day 4 to reconstitute their immune systems and allow for adaptive immune responses to occur in a xenograft model. Direct IT injection of ...
Source: Cancer Control - August 26, 2023 Category: Cancer & Oncology Authors: Michael L Monaco Omer A Idris Grace A Filpi Steven L Kohler Scott D Haller Jeffery E Burr Robert Eversole Karim Essani Source Type: research
Viscoelastic testing: Critical appraisal of new methodologies and current literature
Int J Lab Hematol. 2023 Aug 9. doi: 10.1111/ijlh.14144. Online ahead of print.ABSTRACTUnited States Food and Drug Administration (FDA)-approved viscoelastic testing (VET) methodologies have significantly changed in the last 10 years, with the availability of cartridge-based VET. Some of these cartridge-based methodologies use harmonic resonance-based clot detection. While VET has always allowed for the evaluation of real-time clot formation, cartridge-based VET provides increased ease of use as well as greater portability and robustness of results in out-of-laboratory environments. Here we review the use of VET in a variet...
Source: International Journal of Laboratory Hematology - August 10, 2023 Category: Hematology Authors: Geoffrey D Wool Timothy Carll Source Type: research
Contemporary Monoclonal Antibody Utilization in Glomerular Diseases
Mayo Clin Proc Innov Qual Outcomes. 2023 Jun 30;7(4):276-290. doi: 10.1016/j.mayocpiqo.2023.04.009. eCollection 2023 Aug.ABSTRACTTherapeutic monoclonal antibodies (MAbs) have been one of the fastest growing drug classes in the past 2 decades and are indicated in the treatment of cancer, autoimmune disorders, solid organ transplantation, and glomerular diseases. The Food and Drug Administration has approved 100 MAbs between 1986 and 2021, and MAbs account for 20% of Food and Drug Administration's new drug approval every year. MAbs are preferred over traditional immunosuppressive agents because of their high specificity, red...
Source: Cancer Control - July 14, 2023 Category: Cancer & Oncology Authors: Iyad Mansour Sangeetha Murugapandian Bekir Tanriover Bijin Thajudeen Source Type: research
Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials
Lancet Respir Med. 2023 May 22:S2213-2600(23)00155-8. doi: 10.1016/S2213-2600(23)00155-8. Online ahead of print.ABSTRACTBACKGROUND: Targeting short-term improvements in multicomponent risk scores for mortality in patients with pulmonary arterial hypertension (PAH) could result in improved long-term outcomes. We aimed to determine whether PAH risk scores were adequate surrogates for clinical worsening or mortality outcomes in PAH randomised clinical trials (RCTs).METHODS: We performed an individual participant data meta-analysis of RCTs selected from PAH trials provided by the US Food and Drug Administration (FDA). We calcu...
Source: Respiratory Care - May 25, 2023 Category: Respiratory Medicine Authors: Bryan S Blette Jude Moutchia Nadine Al-Naamani Corey E Ventetuolo Chao Cheng Dina Appleby Ryan J Urbanowicz Jason Fritz Jeremy A Mazurek Fan Li Steven M Kawut Michael O Harhay Source Type: research
UCLA-led study uses base editing to correct mutation that causes rare immune deficiency
Key takeawaysA condition called CD3 delta SCID is caused by a mutation in the CD3D gene, which prevents the production of the CD3 delta protein that is needed for the normal development of T cells from blood stem cells.UCLA researchers showed that a new genome editing technique called base editing can correct the mutation that causes CD3 delta SCID in blood stem cells and restore their ability to produce T cells.Base editing is an ultraprecise form of genome editing that enables scientists to correct single-letter mutations in DNA.A new UCLA-led study suggests that advanced genome editing technology could be used as a ...
Source: UCLA Newsroom: Health Sciences - March 20, 2023 Category: Universities & Medical Training Source Type: news
